Skip to content
Subscriber Only

This French Biotech Is Pushing Its Peanut Allergy Patch Despite a Failed Study

1508162270_GettyImages-81741042

Photographer: Saul Loeb/AFP/Getty Images

DBV Technologies SA’s top priority is to win over U.S. regulators and get its experimental peanut allergy patch to pharmacy shelves by 2019, even after it failed in an important test.

The French biotech expects to hold a meeting with Food and Drug Administration representatives next year, the first contact since late October, when its Viaskin patch wasn’t as effective as had been hoped in the study, called Pepites, Chief Operating Officer David Schilansky said in a telephone interview on Monday. The company still aims to file an application for approval next year.